Shockwave will purchase outstanding Neovasc shares for $27.25 each, valuing the company at around $100 million, according to a Jan. 17 news release from Shockwave. Neovasc specializes in the treatment of refractory angina.
Neovasc’s board approved the transaction, which is expected to close in the first half of 2023.
